Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
505
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multidisciplinary Approach to Addressing Barriers in Osteoporosis Screening, Diagnosis, Therapy Sequencing, and Adherence in India.

Cureus·2026
Same author

The Carbothalamus: Villain and Victim in Metabolic Care.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Inhaled Insulin: Place in Therapy.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Meta-Pharmacologic Support and Scaffolding for Obesity Therapy.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Novel Clinical and Pre-clinical Obesity Estimates in Older Indian Adults: Insights from a Nationally Representative Dataset.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same author

Global trends in the prevalence of type 2 diabetes mellitus: understanding trajectories through conceptual frameworks.

Hormones (Athens, Greece)·2026

Related Experiment Video

Updated: Jan 9, 2026

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

10.2K

Glucodynia.

Sanjay Kalra1, Navneet Agrawal2, Nitin Kapoor3

  • 1Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, India.

JPMA. the Journal of the Pakistan Medical Association
|December 11, 2025
PubMed
Summary
This summary is machine-generated.

We introduce glucodynia, a term for pain in diabetes patients, encompassing sensory and emotional experiences. This condition arises from various factors, including microvascular, metabolic, and medication-related causes, and can be managed with specific therapies.

Keywords:
Diabetic neuropathy, glucodynia, pain, paresthesia, person centered

More Related Videos

Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina
07:04

Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina

Published on: March 14, 2025

714
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.4K

Related Experiment Videos

Last Updated: Jan 9, 2026

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

10.2K
Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina
07:04

Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina

Published on: March 14, 2025

714
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.4K

Area of Science:

  • Endocrinology
  • Neurology
  • Pain Medicine

Background:

  • Pain is a common complication in patients with diabetes mellitus.
  • Diabetic pain can be both detrimental and protective, impacting quality of life.
  • Existing terminology does not fully capture the complexity of pain in diabetes.

Purpose of the Study:

  • To propose and define a new term, 'glucodynia,' for the pain experienced by individuals with diabetes.
  • To elucidate the diverse mechanisms underlying glucodynia.
  • To outline therapeutic strategies for managing pain in diabetic patients.

Main Methods:

  • Literature review and synthesis of existing research on pain mechanisms in diabetes.
  • Conceptual framework development for the term 'glucodynia'.
  • Categorization of potential causes of glucodynia.

Main Results:

  • Glucodynia is defined as an unpleasant sensory and emotional experience associated with diabetes.
  • Identified potential causes include microvascular, musculoskeletal, metabolic, mood-related, and iatrogenic factors.
  • A comprehensive overview of pain mechanisms in diabetes is presented.

Conclusions:

  • The term 'glucodynia' offers a unified concept for understanding diabetes-related pain.
  • Recognizing the multifactorial nature of glucodynia is crucial for effective management.
  • Therapeutic modalities exist to alleviate pain sensation in patients with diabetes.